Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01767454 |
| Title | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | GlaxoSmithKline |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Los Angeles | California | 90025 | United States | Details | |
| GSK Investigational Site | San Francisco | California | 94115 | United States | Details | |
| GSK Investigational Site | Boston | Massachusetts | 02215 | United States | Details | |
| GSK Investigational Site | Saint Louis | Missouri | 63110 | United States | Details | |
| GSK Investigational Site | New York | New York | 10065 | United States | Details | |
| GSK Investigational Site | Nashville | Tennessee | 37232 | United States | Details | |
| GSK Investigational Site | Houston | Texas | 77030 | United States | Details |